| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/27/2013 | CN102993303A Anti-interferon- alpha antibodies |
| 03/27/2013 | CN102993302A Novel anti-Il 13 antibodies and uses thereof |
| 03/27/2013 | CN102993300A Duck tembusu virus polyclonal antibody and preparation method thereof |
| 03/27/2013 | CN102993292A AFP (Alpha Fetal Protein) recombinant protein and in-intro recombinant expression method |
| 03/27/2013 | CN102993265A Immune receptor regulator couplet as well as preparation method and application thereof, coupling precursor for preparing immune receptor regulator couplet and compound for compounding coupling precursor |
| 03/27/2013 | CN102989010A Porcine epidemic diarrhea virus genetic engineering subunit oral vaccine |
| 03/27/2013 | CN102988988A Pharmaceutical composition for treating pulmonary aspergillosis |
| 03/27/2013 | CN102988984A Aqueous drug preparation of anti-TNF (tumor necrosis factor)-alpha human monoclonal antibody for strengthening stability |
| 03/27/2013 | CN102988983A Anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition |
| 03/27/2013 | CN102988982A Method for preparing nano aluminum hydroxide gel adjuvant |
| 03/27/2013 | CN102988981A Adjuvant for improving immunization effect of Edwardsiella vaccine and use method of adjuvant |
| 03/27/2013 | CN102988980A Vaccine dilution liquid for enhancing hog cholera lapinized vaccine immunity effect, and its use method |
| 03/27/2013 | CN102988979A Artemisia pollen allergen vaccine lozenge and preparation method thereof |
| 03/27/2013 | CN102988978A Vaccine composition containing porcine circovirus type 2 antigen and haemophilus parasuis antigen, as well as preparation method and application thereof |
| 03/27/2013 | CN102988977A Multivalent vaccine |
| 03/27/2013 | CN102988976A Hepatitis B virus core antigen-DNA (deoxyribonucleic acid) compound vaccine and preparation method thereof |
| 03/27/2013 | CN102988975A Combined hepatitis A and B vaccine and preparation method thereof |
| 03/27/2013 | CN102988974A Method for preparing porcine pseudorabies live vaccine by using passage CEF (chicken embryo fibroblast) |
| 03/27/2013 | CN102988973A Nucleic acid vaccine for kio herpesvirus |
| 03/27/2013 | CN102988972A Method for producing porcine parvovirus inactivated vaccine by using torrent bioreactor |
| 03/27/2013 | CN102988971A Preparation method of porcine epidemic diarrhea virus genetic engineering subunit oral vaccine |
| 03/27/2013 | CN102988970A Foot-and-mouth disease purification vaccine, preparation method and applications thereof |
| 03/27/2013 | CN102988969A DNA vaccine for expressing avian reticuloendotheliosis virus gp90 gene as well as establishment method and application of gene |
| 03/27/2013 | CN102988968A Vaccine utilizing vibrio anguillarum flagellin and application thereof |
| 03/27/2013 | CN102988967A Preparation method of divalent composite adjuvant inactivated vaccine of Riemerella anatipestifer |
| 03/27/2013 | CN102988966A Method, vaccine composition and kit for exciting specific mucosal immunoreaction |
| 03/27/2013 | CN102988959A Modulation of NKG2D |
| 03/27/2013 | CN102988957A Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 03/27/2013 | CN102988417A Use of parasitic biological agents for diseases prevention and control |
| 03/27/2013 | CN102988329A Preparation method and application of yolk antibody microcapsule preparation |
| 03/27/2013 | CN102988301A Preparation method of long-acting sustained-release microspheres containing bevacizumab |
| 03/27/2013 | CN102657870B Vaccine cryoprotectant without composition of gelatin and human albumin |
| 03/27/2013 | CN102526716B Preparation of specific tumor killing cell |
| 03/27/2013 | CN102409028B Enterovirus 71 (EV71) monoclonal antibody and application thereof |
| 03/27/2013 | CN102335198B Production method for tick-borne encephalitis virus horse antiserum |
| 03/27/2013 | CN102327608B Purifying method of encephalitis B vaccine |
| 03/27/2013 | CN102258774B Preparation method of Brucellosis live vaccine and product thereof |
| 03/27/2013 | CN102247604B Angiotensin II receptor 1 type polypeptide-vector vaccine and application thereof |
| 03/27/2013 | CN102199217B Hepatitis B virus multi-epitope fusion protein and preparation method and application thereof |
| 03/27/2013 | CN102190726B Fab segment of human HIV antibody, and coding gene and application thereof |
| 03/27/2013 | CN102160893B Taxus polysaccharide immunologic adjuvant and influenza vaccine containing same |
| 03/27/2013 | CN102099375B Anti-idiotypic monoclonal antibody against envelope protein vp28 of shrimp white spot syndrome virus and the preparation method thereof |
| 03/27/2013 | CN101991848B Synthetic peptide vaccine for swine fever and application thereof |
| 03/27/2013 | CN101984061B Vaccine strains of infectious clones of porcine reproductive and respiratory syndrome virus (PRRSV) and application thereof |
| 03/27/2013 | CN101974472B Marker-free gene deletion attenuated mutant strain of Edwardsiella tarda wild strain as well as relevant preparations and application thereof |
| 03/27/2013 | CN101928728B Method for preparing enterovirus virus-like particle and application thereof |
| 03/27/2013 | CN101928347B Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
| 03/27/2013 | CN101921772B Human antibodies that bind human IL-12 and methods for producing |
| 03/27/2013 | CN101906464B Proteins producing an altered immunogenic response and methods of making and using the same |
| 03/27/2013 | CN101897961B Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines |
| 03/27/2013 | CN101795707B Compositions and methods for microbe storage and delivery |
| 03/27/2013 | CN101791402B Single-component fish vaccine soaking immunologic adjuvant as well as application and use method thereof |
| 03/27/2013 | CN101732706B Method for preparing living paratyphoid vaccine for piglets and product thereof |
| 03/27/2013 | CN101626782B Human antibodies that bind cd22 and uses thereof |
| 03/27/2013 | CN101607985B Monoclonal antibody for anti-human CEA, a composition containing same and application thereof |
| 03/27/2013 | CN101563463B Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus |
| 03/27/2013 | CN101534860B Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
| 03/27/2013 | CN101528777B Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same |
| 03/27/2013 | CN101460628B Biomolecule surface display and uses thereof |
| 03/27/2013 | CN101437550B Real-time detection of influenza virus |
| 03/27/2013 | CN101426523B B cell-based vaccine loaded with the ligand of natural killer T cell and antigen |
| 03/27/2013 | CN101415438B TOLL like receptor 3 antagonists, methods and uses |
| 03/27/2013 | CN101365715B Matrix metalloproteinase 11 vaccine |
| 03/27/2013 | CN101304765B Conjugation of streptococcal capsular saccharides |
| 03/27/2013 | CN101294159B Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of hiv infection |
| 03/27/2013 | CN101293918B Shorten human papilloma virus 16 type L1 protein |
| 03/27/2013 | CN101291954B Modified antigen binding molecules with altered cell signaling activity |
| 03/27/2013 | CN101287765B 基因修饰的抗体组成物 Gene modified antibody composition |
| 03/27/2013 | CN101247830B TWEAK binding antibodies |
| 03/27/2013 | CN101193653B Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies |
| 03/27/2013 | CN101188996B Surface-modified microparticles and methods of forming and using the same |
| 03/27/2013 | CN101171018B Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| 03/27/2013 | CN101137390B Novel angiogensis inhibitor |
| 03/27/2013 | CN101111261B 糖偶联物疫苗 Saccharide conjugate vaccines |
| 03/27/2013 | CN101111154B Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 03/27/2013 | CN101066997B Human antibodies that bind human IL-12 and methods for producing |
| 03/27/2013 | CN101039700B Vaccine conjugate including a human chorionic gonadotropin beta subunit antigen linked to an anti-mannose receptor (mr) antibody |
| 03/27/2013 | CN101014624B Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication |
| 03/27/2013 | CA2790753A1 Prevention and treatment of pain using antibodies to sphingosine-1 phosphate |
| 03/26/2013 | US8404826 Mycobacterial antigens expressed under low oxygen tension |
| 03/26/2013 | US8404820 Human monoclonal antibodies against Bacillus anthracis protective antigen |
| 03/26/2013 | US8404816 Methods for antibody engineering |
| 03/26/2013 | US8404814 Anti-EDB antibody-targeted IL-10 cytokine for therapy of rheumatoid arthritis |
| 03/26/2013 | US8404812 Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same |
| 03/26/2013 | US8404638 Dimer VEGF antagonist formulations |
| 03/26/2013 | US8404459 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
| 03/26/2013 | US8404253 Modified live (JMSO strain) Haemophilus parasuis vaccine |
| 03/26/2013 | US8404252 Yersinia pestis antigens, vaccine compositions, and related methods |
| 03/26/2013 | US8404251 LprG as a chaperone of immune adjuvants |
| 03/26/2013 | US8404250 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 03/26/2013 | US8404249 Polylysine positively charged backbone, oligoarginine branching group, hydroxypropylcellulose viscosity modifying agent; treat wrinkles, hyperhidrosis, neurologic pain, migraine headache, reducing muscle spasms, preventing or reducing acne |
| 03/26/2013 | US8404248 Reassortant influenza B viruses |
| 03/26/2013 | US8404247 Antitoxin and vaccine platform based on nodavirus VLPS |
| 03/26/2013 | US8404245 Immunization of non-human mammals against Streptococcus equi |
| 03/26/2013 | US8404244 Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies |
| 03/26/2013 | US8404243 Peptide adjuvants |
| 03/26/2013 | US8404242 Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| 03/26/2013 | US8404241 Anti-rhesus D monoclonal antibody |
| 03/26/2013 | US8404240 Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment |
| 03/26/2013 | US8404239 Anti-Notch2 NRR antibodies |